Profile data is unavailable for this security.
About the company
Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Company’s portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.
- Revenue in GBP (TTM)--
- Net income in GBP--
- Incorporated2020
- Employees--
- LocationRoquefort Therapeutics PLC85 Great Portland Street,, First FloorLONDON W1W 7LTUnited KingdomGBR
- Phone+44 20 3918 8633
- Websitehttps://www.roquefortplc.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| SVM UK Emerging Fund Plc | 412.00k | 222.00k |
| Mineral & Financial Investments Ltd | 2.28m | 1.44m |
| APQ Global Ltd | 9.84m | 12.55m |
| Alternative Liquidity Fund Ltd | 690.06k | 165.07k |
| Oneiro Energy PLC | 0.00 | -186.59k |
| Vox Valor Capital Ltd | 7.18m | -225.74k |
| Team PLC | 9.43m | -956.00k |
| CEPS plc | 30.51m | 632.00k |
| Primorus Investments PLC | 3.21m | 927.00k |
| Roquefort Therapeutics PLC | -100.00bn | -100.00bn |
| Africa Opportunity Fund Limited | 0.00 | -1.32m |
| British & American Investment Trust Plc | 2.35m | 1.21m |
| Reabold Resources PLC | 0.00 | -5.50m |
| Tern PLC | -11.00m | -12.43m |
